Sparc Secures Exclusive License For Alopecia Areata Treatment

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

SPARC secures exclusive license for Alopecia Areata Treatment

ri-calendar-2-lineNov 2, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced a significant milestone in the field of alopecia areata treatment. In collaboration with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB), SPARC has obtained an exclusive worldwide license for SCD-153, along with all associated patents and patent applications.


Following a comprehensive evaluation under a Material Transfer Agreement (MTA), SPARC progressed to an Option to License Agreement with the esteemed licensors. The Indian regulatory authority, the Drug Controller General of India (DCGI), has granted approval for SPARC's Investigational New Drug (IND) application.


The licensing agreement outlines provisions for upfront payments, milestone-based payments linked to regulatory and sales achievements, and a structured royalty framework based on sales performance. This collaboration underscores SPARC's commitment to pioneering advancements in dermatological solutions.


CEO of SPARC, Anil Raghavan, expressed enthusiasm about this venture, emphasizing its potential to offer a crucial treatment option for alopecia areata. This strategic partnership exemplifies SPARC's dedication to driving innovation through dynamic collaborations with academic institutions. With the successful development of topical SCD-153, SPARC aims to significantly impact the treatment landscape for this dermatological condition.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions